GT20029
GT-20029, also known as AR-PROTAC, is an androgen receptor degradation enhancer which is under development for the treatment of androgenetic alopecia and acne. It is used topically in gel form.
Read “GT-20029” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 8
- Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Next Generation Therapeutics for Androgenetic Alopecia
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
- Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Community 10
- Been off Tressless for a few years - what’s the latest on GT20029?
- Why do I have the feeling that this subreddit is flooded by Kintor employees?
- GT20029 Will Replace Finasteride For Hair Loss
- So is GT20029 available on the grey market anywhere?
- GT20029: How It Works for Hair Loss - Hair Loss “Cure”
- A concern regarding the upcoming androgen degrader drug GT20029
- Anyone immediately lose hope for gt20029 when they realised it’s developed by kintor
- How much will GT20029 cost if it becomes FDA approved?
- GT20029 Big Phase 2 Update Results!
- Where are we with GT20029 ? Realistic Timeline ?